

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3767106

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
GALLEON PHARMACEUTICALS, INC.		12/15/2015
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	OXFORD FINANCE LLC	
<b>Street Address:</b>	133 NORTH FAIRFAX STREET	
<b>City:</b>	ALEXANDRIA	
<b>State/Country:</b>	VIRGINIA	
<b>Postal Code:</b>	22314	
<b>PROPERTY NUMBERS Total: 7</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Patent Number:</b>	9102636	
<b>Application Number:</b>	13306349	
<b>Patent Number:</b>	9162992	
<b>Application Number:</b>	14851715	
<b>Application Number:</b>	14442777	
<b>Application Number:</b>	14776391	
<b>Application Number:</b>	62186468	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Email:</b>	sullivansu@gtlaw.com	
<b>Correspondent Name:</b>	GREENBERG TRAURIG, LLP	
<b>Address Line 1:</b>	1 INTERNATIONAL PLACE	
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110	
<b>ATTORNEY DOCKET NUMBER:</b>	138179.012700	
<b>NAME OF SUBMITTER:</b>	ABDULLAH MALIK	
<b>SIGNATURE:</b>	/Abdullah Malik/	
<b>DATE SIGNED:</b>	03/03/2016	
<b>Total Attachments: 15</b>		

source=47927224\_1#page1.tif  
source=47927224\_1#page2.tif  
source=47927224\_1#page3.tif  
source=47927224\_1#page4.tif  
source=47927224\_1#page5.tif  
source=47927224\_1#page6.tif  
source=47927224\_1#page7.tif  
source=47927224\_1#page8.tif  
source=47927224\_1#page9.tif  
source=47927224\_1#page10.tif  
source=47927224\_1#page11.tif  
source=47927224\_1#page12.tif  
source=47927224\_1#page13.tif  
source=47927224\_1#page14.tif  
source=47927224\_1#page15.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as December 15, 2015, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“**Oxford**”), as collateral agent (in such capacity, “**Collateral Agent**”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and PACIFIC WESTERN BANK, a California state chartered bank (as successor in interest by merger to Square 1 Bank) with an office located at 406 Blackwell Street, Suite 240, Durham, NC 27701 (“**Bank**” or “**Square 1**”) (each a “**Lender**” and collectively, the “**Lenders**”), and GALLEON PHARMACEUTICALS, INC. a Delaware corporation with offices located at 213 Witmer Road, Horsham, PA 19044 (“**Grantor**”).

### RECITALS

A. Lenders agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among the Collateral Agent, Lenders and Grantor dated as of November 25, 2014, as amended by that certain First Amendment to Loan and Security Agreement dated as of May 13, 2015 and that certain Second Amendment to Loan and Security Agreement dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). In accordance with the terms of the Loan Agreement, effective upon the occurrence of the Lenders’ Election Event, Grantor is granting to Collateral Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Notwithstanding the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the ratable benefit of the Lenders, effective upon the occurrence of the Lenders’ Election Event (as defined in the Loan Agreement), a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the grant, assignment and transfer of a security interest as provided herein shall not include (a) “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise or (b) any license or contract, in each case if the granting of a Lien in such license or contract is prohibited by or would constitute a default under the agreement governing such license or contract (but (A) only to the extent such prohibition is enforceable under applicable law and (B) other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-408 or 9-409 (or any other Section) of Article 9 of the Code); provided that upon the termination, lapsing or expiration of any such prohibition, such license or contract, as applicable, shall automatically be subject to the security interest granted in favor of Collateral Agent hereunder and become part of the “Intellectual Property Collateral.”

Grantor hereby represents and warrants that the Copyrights set forth on Exhibit A, the Patents set forth on Exhibit B and the Trademarks set forth on Exhibit C include, among others, all registered Copyrights, Patents and Trademarks of Grantor on the date hereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the ratable benefit of the Lenders under the Loan Agreement, and shall become effective upon the occurrence of the Lenders' Election Event. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Collateral Agent, of any or all other rights, powers or remedies.

[Signature page follows]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

213 Witmer Road  
Horsham, PA 19044

GALLEON PHARMACEUTICALS, INC.

By:  12/15/15  
JOSEPH OLIVERO

Title: CEO

LENDERS:

Address of Lender:

133 North Fairfax Street  
Alexandria, Virginia 22314  
Attn: Legal Department

OXFORD FINANCE LLC, AS COLLATERAL  
AGENT AND AS A LENDER

By: \_\_\_\_\_

Title: \_\_\_\_\_

PACIFIC WESTERN BANK, AS A LENDER

406 Blackwell Street  
Suite 240  
Durham, NC 27701

By: \_\_\_\_\_

Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

213 Witmer Road  
Horsham, PA 19044

GALLEON PHARMACEUTICALS, INC.

By: \_\_\_\_\_

Title: \_\_\_\_\_


LENDERS:

Address of Lender:

133 North Fairfax Street  
Alexandria, Virginia 22314  
Attn: Legal Department

OXFORD FINANCE LLC, AS COLLATERAL  
AGENT AND AS A LENDER

By: \_\_\_\_\_

  
Mark Davis  
Vice President - Finance, Secretary & Treasurer

Title: \_\_\_\_\_

PACIFIC WESTERN BANK, AS A LENDER

406 Blackwell Street  
Suite 240  
Durham, NC 27701

By: \_\_\_\_\_

Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

213 Witmer Road  
Horsham, PA 19044

GALLEON PHARMACEUTICALS, INC.

By: \_\_\_\_\_

Title: \_\_\_\_\_

LENDERS:

Address of Lender:

133 North Fairfax Street  
Alexandria, Virginia 22314  
Attn: Legal Department


OXFORD FINANCE LLC, AS COLLATERAL  
AGENT AND AS A LENDER

By: \_\_\_\_\_

Title: \_\_\_\_\_

PACIFIC WESTERN BANK, AS A LENDER

406 Blackwell Street  
Suite 240  
Durham, NC 27701

By: 

Title: Vice President



EXHIBIT A

Copyrights

<u>Description</u>	Registration/ Application <u>Number</u>	Registration/ Application <u>Date</u>
--------------------	---	---

None

EXHIBIT B

U.S. Patents and Patent Applications

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
Analgesic Compounds, Compositions and Uses Thereof	9,102,636	August 11, 2015
Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases	13/306,349	November 29, 2011
Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases	9,162,992	October 20, 2015
Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases	14/851,715	September 11, 2015
Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same <sup>1</sup>	14/442,777	May 14, 2015
Novel Breathing Control Modulating Compounds, and Methods of Using Same	14/776,391	September 14, 2015
Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same	62/186,468	June 30, 2015

---

<sup>1</sup> This patent (which relates to GAL-160) is in the process of being abandoned.  
BOS 47916291v1

# Foreign Patents and Patent Applications

	<b>GAL-021 (AAH Series)</b>
<b>046602-5016AU1</b>	Australia application no. 2011336764, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016AU2</b>	Mannion, et al., Appln No. 2013267570, filed November 27, 2014. National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016BR1</b>	Brazil application no. BR 11 2013 0134291, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016BR2</b>	Mannion, et al., Appln No. BR 11 2014 029703 7, filed November 27, 2014, National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016CA1</b>	Canada application no. 2819333, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016CA2</b>	Mannion, et al., Appln No. 2,875,012, filed November 27, 2014. National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016CN1</b>	China application no. 2011800662586, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016CN2</b>	Mannion, et al., Appln No. 2013800401320, filed January 28, 2015. National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016EP1</b>	Europe application no. 11845815.7, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”

<b>046602-5016EP2</b>	Mannion, et al., Appln No. EP 13798039.7, filed December 29, 2014. National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016HK2</b>	Mannion, et al., HK Appln No. TBD, filed October 8, 2015. Phase 1 Registration based on EP Patent 13798039.7, which is a regional phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016IN1</b>	India application no. 4917/DELNP/2013, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016IN2</b>	Mannion, et al., Appln No. 10196/DELNP/2014, filed November 29, 2014. National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, which is based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016JP1</b>	Japan application no. 2013-542100, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016JP2</b>	Mannion, et al., Appln No. 2015-515140, filed November 28, 2014. National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016KR1</b>	Korea application no. 10-2013-7016890, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016KR2</b>	Mannion, et al., Appln No. 10-2014-7036621, filed December 26, 2014. National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016SG1</b>	Singapore application no. 201304143-9, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011 “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016SG2</b>	Mannion, et al., Appln No. 11201407964Y, filed November 28, 2014, National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”

<b>046602-5016ZA1</b>	South Africa application no. 201303960, filed November 29, 2011. Based on PCT/US11/62386, filed November 29, 2011; 61/417,777, filed November 29, 2010 and 61/494,268, filed June 7, 2011. “Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases”
<b>046602-5016ZA2</b>	Mannion, et al., Appln No. 2014/09024, filed December 9, 2014. National Phase of PCT application No. PCT/US13/43052, filed May 29, 2013, based on 13/482,837, filed May 29, 2012. “Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases”
	<b>GAL-160<sup>2</sup></b>
<b>046602-5022AU1</b>	Australian Appln No. 2013344653, filed May 4, 2015. National Phase of PCT Application No. PCT/US13/70160, filed November 14, 2013, based on U.S. Provisional Appln No. 61/783,451, filed March 14, 2013 and 61/726,823, filed November 15, 2012. “Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5022EA1</b>	Eurasian Appln No. 201590933, filed June 10, 2015. National Phase of PCT Application No. PCT/US13/70160, filed November 14, 2013, based on U.S. Provisional Appln No. 61/783,451, filed March 14, 2013 and 61/726,823, filed November 15, 2012. “Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5022IN1</b>	Indian Appln No. 3810/DELNP/2015, filed May 5, 2015. National Phase of PCT Application No. PCT/US13/70160, filed November 14, 2013, based on U.S. Provisional Appln No. 61/783,451, filed March 14, 2013 and 61/726,823, filed November 15, 2012. “Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5022JP1</b>	Japanese Appln No. 2015-542789, filed May 14, 2015. National Phase of PCT Application No. PCT/US13/70160, filed November 14, 2013, based on U.S. Provisional Appln No. 61/783,451, filed March 14, 2013 and 61/726,823, filed November 15, 2012. “Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5022KR1</b>	Korean Appln No. 10-2015-7015724, filed June 12, 2015. National Phase of PCT Application No. PCT/US13/70160, filed November 14, 2013, based on U.S. Provisional Appln No. 61/783,451, filed March 14, 2013 and 61/726,823, filed November 15, 2012. “Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5022MX1</b>	Mexican Appln No. MX/a/2015/006120, filed May 14, 2015. National Phase of PCT Application No. PCT/US13/70160, filed November 14, 2013, based on U.S. Provisional Appln No. 61/783,451, filed March 14, 2013 and 61/726,823, filed November 15, 2012. “Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same”

<sup>2</sup> These patents (series 5022 patents which relate to GAL-160) are in the process of being abandoned.  
BOS 47916291v1

<b>046602-5022SG1</b>	Singapore Appln No. 11201503505Q, Natl filing date May 5, 2015. National Phase of PCT Application No. PCT/US13/70160, filed November 14, 2013, based on U.S. Provisional Appln No. 61/783,451, filed March 14, 2013 and 61/726,823, filed November 15, 2012. “Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5022ZA1</b>	South Africa Appln No. 2015/03281, filed May 12, 2015. National Phase of PCT Application No. PCT/US13/70160, filed November 14, 2013, based on U.S. Provisional Appln No. 61/783,451, filed March 14, 2013 and 61/726,823, filed November 15, 2012. “Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same”
	<b>AAPP (GAL-160 Back-Up)</b>
<b>046602-5023AU1</b>	Australian Appln No. 2014234095, filed September 14, 2015. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5023BR1</b>	Brazilian Appln No. TBD, filed TBD. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5023CA1</b>	Canadian Appln No. TBD, filed September 11, 2015. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5023CN1</b>	Chinese Appln No. TBD, filed TBD. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5023EA1</b>	Eurasian Appln No. TBD, filed TBD. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5023EP1</b>	European Appln No. TBD, filed TBD. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5023IN1</b>	Indian Appln No. 8279/DELNP/2015, filed September 11, 2015. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5023JP1</b>	Japanese Appln No. TBD, filed September 14, 2015. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”
<b>046602-5023KR1</b>	Korean Appln No. 10-2015-7029551, filed October 14, 2015. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. “Novel Breathing Control Modulating Compounds, and Methods of Using Same”

<b>046602-5023MX1</b>	Mexican Appln No. TBD, filed TBD. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. "Novel Breathing Control Modulating Compounds, and Methods of Using Same"
<b>046602-5023SG1</b>	Singapore Appln No. 11201507140P, filed September 7, 2015. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. "Novel Breathing Control Modulating Compounds, and Methods of Using Same"
<b>046602-5023ZA1</b> <b>046602.00112</b>	South African Appln No. TBD, filed September 22, 2015. National Phase of PCT Appln No. PCT/US2014/025792, filed March 13, 2014, based on U.S. provisional Appln No. 61/792,185, filed March 15, 2013. "Novel Breathing Control Modulating Compounds, and Methods of Using Same"

Note: For applications marked as "TBD", the national phase filing has commenced and the local Patent Office has yet to issue the filing receipt listing the corresponding filing number and filing date.

EXHIBIT C

Trademarks

Description

Registration/  
Application  
Number

Registration/  
Application  
Date

None



EXHIBIT D

Mask Works

Description

Registration/  
Application  
Number

Registration/  
Application  
Date

None